DRS

Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company’s Technology for Obstructive Sleep Apnea

Thursday, September 23, 2021 - 12:30pm

(the Company or Vivos) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring, announced today the official formation of the Vivos Medical Consortium.

Key Points: 
  • (the Company or Vivos) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring, announced today the official formation of the Vivos Medical Consortium.
  • For decades, the only treatment options for sleep apnea were limited and often invasive, but with the Vivos technology, that has changed dramatically.
  • Commenting on the anticipated impact of the Vivos Medical Consortium, Vivos Chairman and CEO Kirk Huntsman stated, Obstructive sleep apnea is a serious medical problem, yet it is one that, through the use of the Vivos technology, now has a highly effective medical solution that can be delivered by a dentist.
  • Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA).

Simulations Plus Receives New Grant Award From the FDA

Thursday, September 23, 2021 - 1:30pm

Dr. Viera Lukacova , Chief Scientist at Simulations Plus, said: We have been engaged with various groups at the FDA since 2014 on numerous funded research programs focused on physiologically based pharmacokinetic (PBPK) modeling of complex generics and non-oral administration routes.

Key Points: 
  • Dr. Viera Lukacova , Chief Scientist at Simulations Plus, said: We have been engaged with various groups at the FDA since 2014 on numerous funded research programs focused on physiologically based pharmacokinetic (PBPK) modeling of complex generics and non-oral administration routes.
  • Under the cooperative agreement, FDA and Simulations Plus scientific and program staff will actively assist and participate in project activities in a partnership role with several leading pharmaceutical, generic, consumer goods, and contract research organizations.
  • Jessica Spires and Manas Shah, Senior Scientists II at Simulations Plus, will serve as principal investigators and have primary responsibility for the scientific, technical, and programmatic aspects of the award and day-to-day management of the project.
  • Simulations Plus will own all intellectual property developed within the GastroPlus program, and updates will be integrated into future versions of the optional dermal module.

National Specialized Health Care Leader Launches Integrated Whole Health Clinics

Thursday, September 23, 2021 - 2:00pm

We are extremely proud of the care we continue to provide in Kentucky and eager to expand this model of care to additional geographical areas.

Key Points: 
  • We are extremely proud of the care we continue to provide in Kentucky and eager to expand this model of care to additional geographical areas.
  • Sevita's national presence and their relationships with states and health plans makes them an ideal partner for this venture.
  • It is a unique opportunity for us to create an innovative integration of care between home and clinic settings."
  • Sevita is a leading provider of home and community-based specialized health care.

WELL Health to Acquire Aware MD, Canada's Largest Cardiology Specific Outpatient EMR to Better Support Cardiologists Across Canada

Thursday, September 23, 2021 - 12:00pm

Aware MD, Canada's largest cardiology specific outpatient EMR(2) supports approximately 400 healthcare specialists including over 300 cardiologists providing care for over 2 million patients in Ontario.

Key Points: 
  • Aware MD, Canada's largest cardiology specific outpatient EMR(2) supports approximately 400 healthcare specialists including over 300 cardiologists providing care for over 2 million patients in Ontario.
  • WELL's subsidiary, MyHealth Partners ("MyHealth") has been an early user of Aware MD'S Cerebrum EMR to deliver high quality patient care in cardiology.
  • Aware MD is the provider of Cerebrum, a clinical software for numerous disease specialties, utilized by healthcare specialists mainly in Ontario, and Canada's largest cardiology specific outpatient EMR(2).
  • Cardiology specific EMR means an EMR (Electronic Medical Records) or practice management tool used by cardiologists that includes a DICOM viewer.

Urgent call to physicians to seek the education needed to help patients use food-as-medicine to protect against the most common lifestyle and communicable diseases

Wednesday, September 22, 2021 - 2:10pm

As the emerging power of plant-based dietary lifestyle is confirmed in the growing database of research, it is urgent that physicians, healthcare practitioners and other health leaders expand their education through a trusted CME-accredited educational content provider.

Key Points: 
  • As the emerging power of plant-based dietary lifestyle is confirmed in the growing database of research, it is urgent that physicians, healthcare practitioners and other health leaders expand their education through a trusted CME-accredited educational content provider.
  • Then they will be equipped to effectively treat and counsel their patients with this critical lifesaving information.
  • With most practicing physicians having received, on average, only 20 hours of clinical nutrition education during their entire medical training, there is a gaping void in medical education.
  • The 9th annual Int'l Plant-Based Nutrition Healthcare Conference , September 24-27, 2021 will present the unbiased, evidence-based clinical nutrition education needed by so many medical professionals during these unprecedented times.

NuVasive Partners with Scoliosis Research Society in Ongoing Double Diamond Sponsorship

Wednesday, September 22, 2021 - 12:00pm

SAN DIEGO, Sept. 22, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its long-standing partnership with the Scoliosis Research Society (SRS) with a double diamond sponsorship and will attend the society's 56th Annual Meeting from September 22 to 25, 2021 in St. Louis, Mo.

Key Points: 
  • Since 2007, NuVasive has partnered with SRSthe premier international society aimed at fostering optimal care for all patients with spinal deformities.
  • The Company's ongoing double diamond sponsorship supports clinical workshops, hands-on educational courses, and fellowship and grants for more than 1,000 leading clinicians in spinal deformity around the globe.
  • As part of the SRS annual meeting, NuVasive will host a workshop titled "Advanced applications of Reline 3D in treating complex spinal deformity" presented by Drs.
  • NuVasive, Inc.(NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives.

C₂N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology

Tuesday, September 21, 2021 - 9:29pm

The company is using this start-of-the-art federally regulated CLIA lab for its clinical diagnostic testing services.

Key Points: 
  • The company is using this start-of-the-art federally regulated CLIA lab for its clinical diagnostic testing services.
  • CNs PrecivityAD test is a breakthrough blood test intended for use in patients with cognitive impairment.
  • The test helps physicians determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimers disease.
  • In addition, The Journal of the American Medical Association Neurology published findings from BioFINDERs large comparison of blood plasma amyloid-beta assays.

Northern Vertex Mining Corp. Announces Effective Date for Share Consolidation and Name Change

Tuesday, September 21, 2021 - 9:05pm

The Company has received approval of the Consolidation and the Name Change from the TSX Venture Exchange (the "Exchange").

Key Points: 
  • The Company has received approval of the Consolidation and the Name Change from the TSX Venture Exchange (the "Exchange").
  • Following the Consolidation, the Company will have approximately 60,863,620 post-Consolidation common shares issued and outstanding prior to rounding for fractional shares.
  • Following the Effective Date, Computershare will automatically mail new DRS statements representing post-Consolidation common shares of Elevation Gold Mining Corporation to registered shareholders currently holding their Northern Vertex common shares by DRS statements.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/northern-vertex-mining-corp-ann...
    SOURCE Northern Vertex Mining Corp.

As Physicians Across the Country Struggle with Pandemic Burnout, Semi-Retired MD Teaches an Alternative: Invest in Real Estate

Tuesday, September 21, 2021 - 2:28pm

The course teaches physicians, high-income professionals, and their spouses the same step-by-step process that physician couple Letizia Alto, M.D.

Key Points: 
  • The course teaches physicians, high-income professionals, and their spouses the same step-by-step process that physician couple Letizia Alto, M.D.
  • According to a recent study by The Physicians Foundation, the impact of the COVID-19 pandemic on the health and wellbeing of physicians has been negative.
  • The physician couple began Semi-Retired MD as a blog to educate physicians about real estate investing.
  • Their flagship online course, Zero to Freedom Through Cashflowing Rentals, teaches doctors and high-income earners a step-by-step process for investing in real estate.

New Study Finds Statistically Significantly Faster Healing Rates for Diabetic Wound Patients Treated with Kerecis Fish Skin

Monday, September 20, 2021 - 9:53pm

A study published in the peer-reviewed journal Wounds reports statistically significantly higher healing rates for diabetic foot ulcers (DFUs) treated with Kerecis Omega3 fish skin compared to DFUs treated with Fibrocol, a collagen-alginate dressing.

Key Points: 
  • A study published in the peer-reviewed journal Wounds reports statistically significantly higher healing rates for diabetic foot ulcers (DFUs) treated with Kerecis Omega3 fish skin compared to DFUs treated with Fibrocol, a collagen-alginate dressing.
  • Of the patients treated with the Kerecis product , 67% had healed after 12 weeks of treatment versus 32% in the control group.
  • These statistically significant results may give new hope to patients suffering from diabetic foot ulcers and other wounds, explained Kerecis founder and CEO Fertram Sigurjonsson.
  • The doctors in this study documented the healing efficacy of the Kerecis Omega3 fish-skin graft technology.